MKI67 and breast cancer: While the full analysis is awaited, these 5-year results do provide prospective data supporting the safe omission of adjuvant whole breast radiation in precisely selected luminal A breast cancers with a low Ki-67 index (≤13.25%), quantified using a standardized, validated, decentralized IHC assay [77].